Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$41.96 USD
-1.05 (-2.44%)
Updated May 7, 2024 04:00 PM ET
After-Market: $41.94 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 61 - 80 ( 325 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Commercial Execution Remains Solid for RARE in 2Q22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
RARE Buys an Angel(man drug) - Updated GTX-102 Data Arrives
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Creative Financing On Display With Crysvita, OMERS Transaction
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Continuing to Advance Angelman Program, Adding On To the Commercial Portfolio
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Commercial Biotech Preview: Getting The Ducks In A Row
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Crysvita 2022 Guidance and Recent Corporate Updates; Fireside Chat with the CEO on Thursday
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provides FY21 Crysvita, Dojolvi Revenue; FY22 Guidance Targets
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Anticipated Angelman Update Arrives - Looking Towards Mid-2022 Data Point
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L